Hexis Lab is a technology company working at the forefront of raw material innovation. Hexis Lab produce ground-breaking ethnically targeted skincare products to protect and repair sun-damaged skin and improve life well-being. The company's discovery platform utilizes big data cloud computing approaches and in-silico computer modelling to screen a huge database of natural plant derived compounds for activity against our selected cellular targets.
Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.
QV Bioelectronics is striving to deliver longer, better quality lives to brain tumour patients through their first of its kind electric field therapy implant, GRACE. GRACE has been designed alongside some of the leading neurosurgeons in the UK, with the aim of extending patient life expectancy without impacting patient quality of life. For patients with the most common primary brain tumour, glioblastoma, there has been a severe lack of new, effective treatments for decades, with only a handful of approved options. Because of this, glioblastoma has some of the worst outcomes of any cancer, with a 5-year survival rate of <5. Co-founder and academic neurosurgeon Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for patients but also by major design flaws in newer electric field therapy approaches. Working together with Dr Chris Bullock, a biomedical engineer who had been carrying out research at Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. QV Bioelectronics was founded to their solution GRACE, to patients. Since then, their ground-breaking materials science research has received nearly $1M in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK, as well as over $1M in equity funding from international life science seed investors SOSV, and renowned life-science investors in Consilience & Catapult Ventures. QV now have an expert, multidisciplinary team with decades of experience working bringing GRACE to the clinic from their research hub in Alderley Park, Cheshire.
EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials.
FLY Mama is a trauma-informed integrated healthcare solution for pre and postpartum well-being available online. Its vision is to launch an employee benefit programme to help women during and after pregnancy, including perinatal trauma and loss support.
52 North Health aims to improve healthcare with a medical device that uses artificial intelligence (AI) to determine the risk of neutropenic sepsis for patients undergoing chemotherapy.
Their management team has extensive experience within the biopharmaceutical industry, and a wealth of knowledge in building successful biotechnology companies. They are developing novel therapeutic antibody approaches to target a fundamental control pathway associated with several major diseases. These novel approaches give aTen Therapeutics the potential to develop powerful new treatments to extend and improve lives.
Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.
BIOStress is revolutionizing the understanding and management of stress. We have developed a unique and world-leading algorithm that accurately measures stress using available biometric devices. We are using this to objectively monitor workplace stress and make improvements to wellbeing and performance.
Healthcare marketplace is broken from a long-time. Both buyers (hospitals, health systems) and suppliers (pharmaceutical and medical device manufacturers/digital health companies/service or solution providers) struggle to find the optimum opportunities for developing a transaction. It takes time and resources to effectively commercialise new healthcare technology. We use the latest data automation technologies (NLP, ML, DL etc). to aggregate demand from millions of sources and provide real-time analytics to shape the transaction. We aggregate more than $2tn of global demand (70+ countries) in our system and make it easier for healthcare companies to start closing more deals. Our customers use a range of search and bid-development tools within our platform to quickly find the most suitable opportunity and finalise a transaction. Additionally, buyers (hospital, clinics etc.) can directly launch procurement and sourcing programs in our platform and get access to thousands of suppliers in the market for their respective products/services. We have millions of contracts in our platform across countries for suppliers to bid, we have onboarded some of the world's most innovative healthcare companies, we are continuing to raise money to build the world's first digital marketplace, we have won innovation awards, and we're backed by some of the best investors in the world. And we are JUST GETTING STARTED.
Abtrace is a provider of AI-based solutions that scale medical expertise. It eliminates duplication and improves patient safety while saving GP time and lowering practice costs. Machine learning is used to provide advanced digital solutions that allow healthcare professionals to react to and manage the patient's current diseases, as well as recognize the first clinical signs of new conditions. The software enables general practitioners (GPs) and healthcare assistants (HCAs) to make informed decisions, automate key aspects of disease monitoring, and ensure patients receive effective care.
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides. In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.
Invatech Health provides software as a service solution. It also develops several products to address unresolved issues in areas such as domiciliary care and mental health. It specializes in the healthcare and social care industries.
Healthcare marketplace is broken from a long-time. Both buyers (hospitals, health systems) and suppliers (pharmaceutical and medical device manufacturers/digital health companies/service or solution providers) struggle to find the optimum opportunities for developing a transaction. It takes time and resources to effectively commercialise new healthcare technology. We use the latest data automation technologies (NLP, ML, DL etc). to aggregate demand from millions of sources and provide real-time analytics to shape the transaction. We aggregate more than $2tn of global demand (70+ countries) in our system and make it easier for healthcare companies to start closing more deals. Our customers use a range of search and bid-development tools within our platform to quickly find the most suitable opportunity and finalise a transaction. Additionally, buyers (hospital, clinics etc.) can directly launch procurement and sourcing programs in our platform and get access to thousands of suppliers in the market for their respective products/services. We have millions of contracts in our platform across countries for suppliers to bid, we have onboarded some of the world's most innovative healthcare companies, we are continuing to raise money to build the world's first digital marketplace, we have won innovation awards, and we're backed by some of the best investors in the world. And we are JUST GETTING STARTED.
Healthcare marketplace is broken from a long-time. Both buyers (hospitals, health systems) and suppliers (pharmaceutical and medical device manufacturers/digital health companies/service or solution providers) struggle to find the optimum opportunities for developing a transaction. It takes time and resources to effectively commercialise new healthcare technology. We use the latest data automation technologies (NLP, ML, DL etc). to aggregate demand from millions of sources and provide real-time analytics to shape the transaction. We aggregate more than $2tn of global demand (70+ countries) in our system and make it easier for healthcare companies to start closing more deals. Our customers use a range of search and bid-development tools within our platform to quickly find the most suitable opportunity and finalise a transaction. Additionally, buyers (hospital, clinics etc.) can directly launch procurement and sourcing programs in our platform and get access to thousands of suppliers in the market for their respective products/services. We have millions of contracts in our platform across countries for suppliers to bid, we have onboarded some of the world's most innovative healthcare companies, we are continuing to raise money to build the world's first digital marketplace, we have won innovation awards, and we're backed by some of the best investors in the world. And we are JUST GETTING STARTED.
4Degra® is a unique, patent-protected platform technology and is the ONLY route to 3D-printing high resolution biodegradable medical devices. The technology boosts excellent 3D-printing resolution, unique tunability in strength, elasticity and biodegrability as well as outstanding shape memory properties. Game-changing properties in themselves PLUS the ability to 3D-print medical devices from nano to macro scale will lead to far superior patient experiences compared with the next best alternatives.
Abtrace is a provider of AI-based solutions that scale medical expertise. It eliminates duplication and improves patient safety while saving GP time and lowering practice costs. Machine learning is used to provide advanced digital solutions that allow healthcare professionals to react to and manage the patient's current diseases, as well as recognize the first clinical signs of new conditions. The software enables general practitioners (GPs) and healthcare assistants (HCAs) to make informed decisions, automate key aspects of disease monitoring, and ensure patients receive effective care.
Decorte Future Industries is a venture-backed startup deploying AI to extract health data directly from sound.
BioFab is developing innovative new products for healthcare diagnostics with a particular focus on point-of-care testing (POCT) applications. Our vision is to create a truly universal diagnostic platform that can bring the clinical lab to the patient. Our innovative approach will enable this vision by offering a diverse range of test cartridges which can run on a single, universal reader device. It will not need any user training and will simply require the addition of the patient sample. Fully automated processing will then take place in a totally enclosed cartridge and will then deliver laboratory grade results without risk of cross-contamination. We are developing a test for Covid-19 with the support of an Innovate UK Smart award and will expand the product range to cover cardio-vascular disease, respiratory/gastric infections, blood infections (sepsis), STDs, Cancer and other conditions. We also have the ability to access the rapidly expanding Chinese market and have route-to-market and manufacturing base via established partners in China.
Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.
Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers.
QV Bioelectronics is striving to deliver longer, better quality lives to brain tumour patients through their first of its kind electric field therapy implant, GRACE. GRACE has been designed alongside some of the leading neurosurgeons in the UK, with the aim of extending patient life expectancy without impacting patient quality of life. For patients with the most common primary brain tumour, glioblastoma, there has been a severe lack of new, effective treatments for decades, with only a handful of approved options. Because of this, glioblastoma has some of the worst outcomes of any cancer, with a 5-year survival rate of <5. Co-founder and academic neurosurgeon Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for patients but also by major design flaws in newer electric field therapy approaches. Working together with Dr Chris Bullock, a biomedical engineer who had been carrying out research at Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. QV Bioelectronics was founded to their solution GRACE, to patients. Since then, their ground-breaking materials science research has received nearly $1M in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK, as well as over $1M in equity funding from international life science seed investors SOSV, and renowned life-science investors in Consilience & Catapult Ventures. QV now have an expert, multidisciplinary team with decades of experience working bringing GRACE to the clinic from their research hub in Alderley Park, Cheshire.
Thomson Screening is a supplier of software for health needs assessments, immunisations, and health screening. They offer schoolscreener software for managing and automating health program requirements. They also provide workscreener platform to provide critical health information to employers across sectors, such as the private sector and the public sector.
Whether you're a patient recovering from knee surgery or a desk worker starting to feel an ache in your back, the first step to getting you back to your best is getting an accurate measurement of your issue. Vitrue's products accurately and objectively measure musculoskeletal issues from the workplace to the clinic. VIDA is a tech-driven, fully managed service to reduce musculoskeletal problems like back and neck pain in desk workers. All while making companies DSE compliant for remote, office and hybrid teams. By assessing the quality of desk workers’ workspaces through cutting-edge AI, VIDA is a modern and scalable solution with impactful benefits. 65% of employees are living with MSK issues like back or neck pain. In most cases, this is entirely preventable. With VIDA, you can empower your team to improve their workspace by giving them the knowledge they need to reduce pain and improve their quality of life. Vitrue EVVA uses depth sensors to perform clinical grade assessments of patients and is used in orthopaedics, elite sport injury prevention and preventative health screening. We provide computer vision based biomechanics measurement technology to assess your clients’ performance of gold standard functional movements pre and post treatment and throughout rehabilitation. We provide data to both clinicians and patients to ensure issues are detected early, optimal treatment can be designed and patients are informed and engaged throughout their experience. Our mission is to provide a new foundation for musculoskeletal healthcare and reduce MSK pain in millions of people.
Healthcare marketplace is broken from a long-time. Both buyers (hospitals, health systems) and suppliers (pharmaceutical and medical device manufacturers/digital health companies/service or solution providers) struggle to find the optimum opportunities for developing a transaction. It takes time and resources to effectively commercialise new healthcare technology. We use the latest data automation technologies (NLP, ML, DL etc). to aggregate demand from millions of sources and provide real-time analytics to shape the transaction. We aggregate more than $2tn of global demand (70+ countries) in our system and make it easier for healthcare companies to start closing more deals. Our customers use a range of search and bid-development tools within our platform to quickly find the most suitable opportunity and finalise a transaction. Additionally, buyers (hospital, clinics etc.) can directly launch procurement and sourcing programs in our platform and get access to thousands of suppliers in the market for their respective products/services. We have millions of contracts in our platform across countries for suppliers to bid, we have onboarded some of the world's most innovative healthcare companies, we are continuing to raise money to build the world's first digital marketplace, we have won innovation awards, and we're backed by some of the best investors in the world. And we are JUST GETTING STARTED.
AreteMedical is enabling early intervention and precision management of asthma, COPD, and other chronic lung disease. We do this with a patented platform, which for the first time unites the two key data types for these diseases: inflammation and airflow mechanics. This platform will let specialist-grade data be available in primary care, then at home for people with severe/unstable disease. Our vision is to be for asthma, the equivalent that CGM is for diabetes.
AreteMedical is enabling early intervention and precision management of asthma, COPD, and other chronic lung disease. We do this with a patented platform, which for the first time unites the two key data types for these diseases: inflammation and airflow mechanics. This platform will let specialist-grade data be available in primary care, then at home for people with severe/unstable disease. Our vision is to be for asthma, the equivalent that CGM is for diabetes.
ExplantLab is an independent research organisation exploring the links between patient genetics & the design, manufacture & performance of medical devices.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials. We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products. Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Epidarex Capital invests in early-stage, high growth life science and health technology Epidarex Capital is a transatlantic venture fund that invests in early-stage, high growth life science and health technology companies in under-ventured markets.
Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology.
CellRev is a biotechnology company focused on process intensification within cell manufacturing applications. The company’s proprietary technology facilitates the transition from batch to continuous processing of adherent cells. It’s a disruptive new biomanufacturing approach that increases yield while decreasing operating costs and capital expenditure. A proprietary cell detachment process is complemented by a specially designed bioprocess; together, they pose an altogether unique cell manufacturing solution.
Ixaka is a regenerative medicine company focused on developing advanced cell-based therapeutics aimed at treating serious diseases that lack effective existing therapies. The company is actively conducting clinical trials for its cellular therapies, with the goal of obtaining marketing authorization in Europe, the United States, and other global markets. Ixaka's approach is grounded in a deep understanding of the fundamental science behind cell therapies. Collaborating with the Andalusian Health Authority and the Andalusian Initiative of Advanced Therapies, Ixaka is working to expand its portfolio of cell therapies to address additional indications with significant unmet medical needs.
Ampersand is pioneering the development of behavioural science based digital medicines for people living with long term inflammatory conditions. We deliver measurable improvements in mental health and quality of life for patients and significant, well-evidenced savings for healthcare providers.
The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. They are based on the 12th floor of Guy’s Hospital in central London, with over 120 cell and gene therapy experts, state-of-the art development and viral vector laboratories. They are also building a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials. We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products. Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Aglaris is developing an automated cell culture bioreactor for the mass production of human stem cells. Aglaris produces equipment to ensure cell and tissue culture is an easy, problem-free task. By automating and controlling the cell culture processes, we can obtain cells and tissues with sufficient quality to revitalize regenerative medicine and cell therapies. The technology used by our equipment is unique and is protected by international patents.
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer. Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treat age-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies. Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.
Whether you're a patient recovering from knee surgery or a desk worker starting to feel an ache in your back, the first step to getting you back to your best is getting an accurate measurement of your issue. Vitrue's products accurately and objectively measure musculoskeletal issues from the workplace to the clinic. VIDA is a tech-driven, fully managed service to reduce musculoskeletal problems like back and neck pain in desk workers. All while making companies DSE compliant for remote, office and hybrid teams. By assessing the quality of desk workers’ workspaces through cutting-edge AI, VIDA is a modern and scalable solution with impactful benefits. 65% of employees are living with MSK issues like back or neck pain. In most cases, this is entirely preventable. With VIDA, you can empower your team to improve their workspace by giving them the knowledge they need to reduce pain and improve their quality of life. Vitrue EVVA uses depth sensors to perform clinical grade assessments of patients and is used in orthopaedics, elite sport injury prevention and preventative health screening. We provide computer vision based biomechanics measurement technology to assess your clients’ performance of gold standard functional movements pre and post treatment and throughout rehabilitation. We provide data to both clinicians and patients to ensure issues are detected early, optimal treatment can be designed and patients are informed and engaged throughout their experience. Our mission is to provide a new foundation for musculoskeletal healthcare and reduce MSK pain in millions of people.
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space.
SageTech is recycling inhalational anaesthetic agents using patented technology to generate significant cost and environmental benefits for healthcare providers. SageTech has developed, prototyped, and patented systems to capture, extract and purify inhalational anaesthetic emissions, creating a circular economy for a formerly wasteful pharmaceutical product
BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer for precision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life. Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board).
Almac Group is a prominent contract development and manufacturing organization based in Craigavon, United Kingdom, specializing in a comprehensive array of services for the pharmaceutical and biotech sectors. With over 40 years of organic growth, the company employs more than 4,500 skilled professionals and operates facilities in the UK, Ireland, the United States, and Asia. Almac Group's offerings encompass research and development, biomarker discovery and development, active pharmaceutical ingredient (API) manufacture, formulation development, clinical trial supply, and companion diagnostic development. The group also includes Almac Diagnostics, which focuses on biomarker discovery and validation, providing services such as bioinformatics solutions and genomic analyses. Additionally, Almac Discovery is dedicated to oncology, concentrating on innovative cancer treatment approaches during the discovery and preclinical stages. Through continuous investment in state-of-the-art technology and services, Almac Group supports clients throughout the entire biopharmaceutical product lifecycle, from preclinical development to commercialization.
Phico Therapeutics is a biotechnology company developing a novel platform technology which it believes could form the basis for a new generation of antibiotics to overcome antibacterial resistance.
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides. In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Vitamica was established in early 2018 as a spin-out company from the University of Bristol. Taking optical technology from the School of Physics, the new company is beginning its journey towards commercialisation of a rapid and novel diagnostic method that has high potential for use in antimicrobial susceptibility testing. With a growing IP portfolio and an active approach to identifying opportunities in healthcare, veterinary and pharma sectors, Vitamica fully intends to make its mark as another successful company to originate from the University of Bristol.
Symbiosis Pharmaceutical Services was established in 2011 in response to increasing global demand for niche, sterile manufacturing specialists that could satisfy product supply needs for clinical trials. We created our purpose-built facility in Stirling, Scotland, specifically designed with biologic and small molecule production capabilities in mind to support biotech and speciality pharmaceutical companies worldwide that require small-scale injectable products. Differing from most CMOs, from the day our operations commenced we offered rapid access to manufacturing slots and quick release of drug products to ensure tight timelines are successfully met. Naturally, this has been a real hit with our clients.
Stratified Medicine Scotland Innovation Centre is based in the University of Glasgow’s Clinical Innovation Zone at the Queen Elizabeth University Hospital (QEUH) campus in Glasgow.SMS-IC is a unique consortium of partners, comprising NHS Scotland, four Scottish Universities(Glasgow, Edinburgh, Dundee and Aberdeen) and industrial partners across informatics and genomics (Aridhia Ltd and ThermoFisher Ltd).
Eagle Genomics is a enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. They help Life Science companies get the maximum value from their R&D data and they are delivering the information architecture for the genomics era. Their suite of software products radically reduces cost and time to complete research, enabling drastic productivity improvements. Their architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Their mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve their customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding. With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries they understand the common challenges facing these industries in the handling of ever growing of data and information resources. Eagle Genomics is at the forefront in addressing the challenges, risks, and opportunities in delivering the enterprise information architecture for the genomics era.
AreteMedical is enabling early intervention and precision management of asthma, COPD, and other chronic lung disease. We do this with a patented platform, which for the first time unites the two key data types for these diseases: inflammation and airflow mechanics. This platform will let specialist-grade data be available in primary care, then at home for people with severe/unstable disease. Our vision is to be for asthma, the equivalent that CGM is for diabetes.
Ixaka is a regenerative medicine company focused on developing advanced cell-based therapeutics aimed at treating serious diseases that lack effective existing therapies. The company is actively conducting clinical trials for its cellular therapies, with the goal of obtaining marketing authorization in Europe, the United States, and other global markets. Ixaka's approach is grounded in a deep understanding of the fundamental science behind cell therapies. Collaborating with the Andalusian Health Authority and the Andalusian Initiative of Advanced Therapies, Ixaka is working to expand its portfolio of cell therapies to address additional indications with significant unmet medical needs.
Cobra Biologics is a leading international contract manufacturing organisation (CMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries. Cobra is a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply. Over 15 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market. We offer a broad range of integrated and stand-alone development services, stretching from cell line development to the supply of investigational medicinal product for clinical trials and commercial market supply.
BioSystems Technology engages in the development of alternative research models. BioSystems Technology was founded by an infectious disease research fellow and a Professor of Molecular Pathogenicity based at the University of Exeter.
Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.
Touchlight Genetics develops a DNA production platform designed for the development of DNA vaccines for oncology and infectious diseases. Founded in 2007, Touchlight brings together a highly talented scientific and drug development team supported by an experienced board. Founder and CEO Jonny Ohlson has assembled a dynamic management team, including Clive Dix, Non-Executive Chairman, and John Tite, Executive Head of Research (formerly founding CEO of Bicycle Therapeutics), with substantial experience in growing life science companies and particularly in DNA vaccines. Touchlight is supported by a group of Non-Executive Directors, who bring a wealth of healthcare and entrepreneurial experience. Led by experienced drug pharmaceutical scientists Neil Porter and Jill Makin, Touchlight’s scientific team- some of the brightest talents in the UK industry- has successfully established and patented the proTLx™ synthetic DNA platform as well as successfully establishing the first therapeutic proof-of-principle through collaboration with leading academic partners. The company has established strong collaborative links with academic laboratories worldwide including Imperial College London, Southampton University, Queen’s University Belfast and the University of Pennsylvania in the US.
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.
CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.
Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.
Binx Health is committed to broadening convenient and equitable access to healthcare. The company's point-of-care diagnostic solutions empower its partners to overcome traditional barriers to care, extend their outreach, and deliver exceptional patient experiences. The binx io point-of-care molecular platform marks a significant milestone as the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males (urine) and females (vaginal swabs). It delivers results comparable to those of central lab performance, typically within about thirty minutes.
Eagle Genomics is a enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. They help Life Science companies get the maximum value from their R&D data and they are delivering the information architecture for the genomics era. Their suite of software products radically reduces cost and time to complete research, enabling drastic productivity improvements. Their architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Their mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve their customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding. With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries they understand the common challenges facing these industries in the handling of ever growing of data and information resources. Eagle Genomics is at the forefront in addressing the challenges, risks, and opportunities in delivering the enterprise information architecture for the genomics era.
Sphere Fluidics Limited is a new Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.
Current Health help healthcare reduces risk & cost by monitoring, managing, and engaging patients at home.
LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF)..
CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.
Isansys Lifecare is a digital healthcare company that has developed a patient status engine and a user-friendly, sophisticated patient monitoring platform. The PSE automates fundamental healthcare procedures. They focused on developing new patient-centered technology and data-driven methods in hospitals and healthcare organizations throughout the world.
Sarissa is developing a range of minimally invasive, microelectrode electrochemical sensors for the measurement of the purines and other neurochemicals, as indicators of neurological activity / disorders and has a product design platform that offers exquisite sensitivity, coupled with a broad linear range and high levels of accuracy and reproducibility. These biosensors are designed for in vitro and in vivo studies for research and diagnostic applications.
Tecrea Ltd is involved in basic research that results in transformative technologies for biomedicine. We focus on creative ways to use nanotechnology to improve cell delivery of reagents and drugs. We view cell delivery as a central problem in biological research and biomedicine, and improved delivery strategies can enable better application of many reagents and drugs. By improving delivery, Tecrea Ltd enables scientists to bring forward modern molecular medicines to the clinic.
Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram They will lead the way through this challenge, using their expertise and experience to unleash the potential of genomics and set the standards by which organisations and patients can benefit from genomic data.
Outcomes Based Healthcare supports outcome-based approaches to the healthcare system. With a unique approach to co-creating outcomes with patients, and through academic and technical rigour to the process of measuring and contracting for outcomes. Developing technology products that support commissioners/payors, health providers track and measure outcomes for population segments; linking health and non-health datasets and using big data to predict health outcomes through machine-learning techniques; smartphone app development in predicting Patient Reported Outcomes. Our team has a diverse set of backgrounds in medicine, business, economics, computer science and web technology- directed to do what we love the most: helping design care that fits around people and enabling the health system to do this through technology.
MICAs novel patented technology utilises magnetic nanoparticles to control cell behaviour inside and outside the body using custom designed and built magnetic arrays. Using this technology we have established a novel dynamic drug screening assay, DYNASCREEN. Further stem cell therapy applications have been explored with ambitions of clinical adoption for the treatment of bone and cartilage injuries. MICA scientists are experienced in functionalising magnetic nanoparticles with any antibody, peptide or small molecule to suit a range of applications.
Locate Bio is a world leading orthobiologics company focused on providing surgeons with best-in-class products. Its clinical-stage product, LDGraft, is a controlled and extended-release rhBMP-2 for the treatment of chronic low back pain. CognitOss is in the discovery phase for the treatment of antimicrobial-resistant (AMR) infections.